专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US12076370B2 Compositions and methods for treating heart failure 有权
公开(公告)号：US12076370B2
公开(公告)日：2024-09-03
申请号：US17576886
申请日：2022-01-14
申请人： Zensun (Shanghai) Science & Technology, Co., Ltd.
发明人： Mingdong Zhou
IPC分类号： A61K38/18 , A61K9/00 , A61K45/06 , C07K14/475 , G01N33/68 , G01N33/74
CPC分类号： A61K38/1883 , A61K9/0019 , A61K45/06 , C07K14/4756 , G01N33/6893 , G01N33/74 , G01N2333/58 , G01N2800/325 , G01N2800/52
摘要： The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.

82. 发明公开

US20240009274A1 Use of NRG-1Beta1 for Detection and/or Treatment of Multiple Sclerosis 审中-公开
公开(公告)号：US20240009274A1
公开(公告)日：2024-01-11
申请号：US18043199
申请日：2021-09-07
申请人： University of Manitoba
发明人： Hardeep Kataria , Soheila Karimi-Abdolrezaee
IPC分类号： A61K38/18 , A61K45/06 , A61P21/00
CPC分类号： A61K38/1883 , A61K45/06 , A61P21/00
摘要： Multiple sclerosis (MS) is characterized by immune mediated neurodegeneration that results in progressive, life-long neurological and cognitive impairments. Yet, the endogenous mechanisms underlying MS pathophysiology are not fully understood. Here, we provide compelling evidence that associates dysregulation of neuregulin-1 beta 1 (Nrg-1β1) with MS pathogenesis and progression. In the experimental autoimmune encephalomyelitis (EAE) model of MS, we demonstrate that Nrg-1β1 levels are abated within spinal cord lesions and peripherally in the plasma and spleen during presymptomatic, onset and progressive course of the disease. We demonstrate that plasma levels of Nrg-1β1 are also significantly reduced in individuals with early MS and is positively associated with progression to relapsing-remitting MS. The functional impact of Nrg-1β1 downregulation preceded disease onset and progression, and its systemic restoration was sufficient to delay EAE symptoms and alleviate disease burden. Intriguingly, Nrg-1β1 therapy exhibited a desirable and extended therapeutic time window of efficacy when administered prophylactically, symptomatically, acutely or chronically. Using in vivo and in vitro assessments, we identified that Nrg-1β1 treatment mediates its beneficial effects in EAE by providing a more balanced immune response. Mechanistically, Nrg-1β1 moderated monocyte infiltration at the blood-central nervous system interface by attenuating chondroitin sulfate proteoglycans and matrix metalloproteinase-9. Moreover, Nrg-1β1 fostered a regulatory and reparative phenotype in macrophages, T helper type 1 (Th1) cells and microglia in the spinal cord lesions of EAE mice. Taken together, our new findings in MS and EAE have uncovered a novel regulatory role for Nrg-1β1 early in the disease course and suggest its potential as a specific therapeutic target to ameliorate disease progression and severity.

83. 发明授权

US09956266B2 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure 有权
公开(公告)号：US09956266B2
公开(公告)日：2018-05-01
申请号：US14928124
申请日：2015-10-30
申请人： Acorda Therapeutics, Inc.
发明人： Anthony O. Caggiano , Anindita Ganguly , Jennifer Iaci , Tom Parry
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： A61K38/1883 , A61K38/18
摘要： The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

84. 发明申请

US20180010091A1 Hydrogel Comprising A Scaffold Macromer Crosslinked With A Peptide And A Recognition Motif 审中-公开
公开(公告)号：US20180010091A1
公开(公告)日：2018-01-11
申请号：US15543866
申请日：2016-01-15
申请人： Massachusetts Institute of Technology
发明人： Linda G. Griffith , Barbara Imperiali , Christi D. Cook , Caroline Chopko Ahrens , Kasper Renggli , Jorge L. Valdez Macias
IPC分类号： C12N5/00 , C08G65/333 , C08J3/24 , C08G65/334 , C08J3/075 , G01N33/574 , G01N33/50
CPC分类号： C12N5/0068 , A61K9/06 , A61K38/1808 , A61K38/1883 , A61K47/10 , A61K47/6903 , C08G65/33396 , C08G65/3342 , C08G2210/00 , C08G2650/04 , C08G2650/20 , C08J3/075 , C08J3/24 , C08J2371/02 , C12N5/0012 , C12N5/0062 , C12N2513/00 , C12N2533/30 , C12N2537/10 , G01N33/5005 , G01N33/574
摘要： Methods of forming, dissolving, and functionalizing an extracellular matrix gel on demand based on cross-linking, modification, and dissolution of hydrogels using transpeptidase (e.g. sortase) are disclosed. Also provided are hydrogels comprising one or more macromers crosslinked to a mixture of peptides, wherein all or a portion of the peptides in the mixture comprise a recognition motif cleavable by a transpeptidase (e.g., sortase).

85. 发明申请

US20170333529A1 NEUREGULIN IN THE TREATMENT OF FIBROTIC DISORDERS 审中-公开
公开(公告)号：US20170333529A1
公开(公告)日：2017-11-23
申请号：US15532485
申请日：2016-01-20
申请人： UNIVERSITEIT ANTWERPEN
发明人： Zarha VERMEULEN , Vincent SEGERS , Gilles DE KEULENAER
IPC分类号： A61K38/18 , A61K48/00
CPC分类号： A61K38/1883 , A61K48/00
摘要： The present invention relates to the treatment of fibrotic disorders. More particularly, the present invention relates to the use of a neuregulin protein in a method treating, preventing and/or delaying fibrotic skin disorders, fibrotic lung disorders or liver cirrhosis.

86. 发明申请

US20160279201A1 METHODS OF TREATING METABOLIC DISORDERS 有权
标题翻译：治疗代谢障碍的方法
公开(公告)号：US20160279201A1
公开(公告)日：2016-09-29
申请号：US14778379
申请日：2014-03-19
申请人： THE REGENTS OF UNIVERSITY OF MICHIGAN
发明人： Jiandie Lin , Guoxiao Wang
IPC分类号： A61K38/18 , A61K45/06
CPC分类号： A61K38/1883 , A61K45/06 , G01N33/6893 , G01N2333/475 , G01N2800/04 , G01N2800/042 , G01N2800/044
摘要： Methods of treating metabolic and/or lipid disorders are provided comprising administering to a patient in need thereof a therapeutically effective amount of Nrg4, an Nrg4 variant, or a biologically active fragment thereof.
摘要翻译：提供了治疗代谢和/或脂质疾病的方法，包括向有需要的患者施用治疗有效量的Nrg4，Nrg4变体或其生物活性片段。

87. 发明授权

US09434777B2 Neuregulin peptides and their use 有权
标题翻译：神经肽肽及其用途
公开(公告)号：US09434777B2
公开(公告)日：2016-09-06
申请号：US14657899
申请日：2015-03-13
申请人： Zensun (Shanghai) Science & Technology Limited
发明人： Mingdong Zhou
IPC分类号： A61K38/00 , A61K38/16 , C07K14/00 , C07K14/475 , A61K38/18
CPC分类号： C07K14/4756 , A61K38/00 , A61K38/16 , A61K38/1883 , C07K14/00
摘要： Neuregulin peptides useful, for example, in methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.
摘要翻译：描述了可用于例如包括预防，治疗或延迟各种疾病或病症的方法和组合物中的神经调节肽。

88. 发明授权

US09352023B2 Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis 有权
标题翻译：使用神经调节蛋白-4治疗炎症性肠病和坏死性小肠结肠炎
公开(公告)号：US09352023B2
公开(公告)日：2016-05-31
申请号：US14236831
申请日：2012-08-15
申请人： Mark R. Frey
发明人： Mark R. Frey
IPC分类号： A61K38/16 , A61K38/18
CPC分类号： A61K38/1883 , G01N33/573 , G01N2333/71 , G01N2440/14 , G01N2500/10 , G01N2800/065
摘要： The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.
摘要翻译：本发明提供了通过施用有效量的包含ErbB4的活化剂的组合物来治疗，抑制和/或降低有需要的受试者的炎症性肠病和坏死性小肠结肠炎的严重性的方法，药物组合物和试剂盒。

89. 发明申请

US20160095903A1 EXTENDED RELEASE OF NEUREGULIN FOR IMPROVED CARDIAC FUNCTION 审中-公开
标题翻译：用于改善心脏功能的NEUREGULIN的扩展释放
公开(公告)号：US20160095903A1
公开(公告)日：2016-04-07
申请号：US14965790
申请日：2015-12-10
申请人： Zensun (Shanghai) Science & Technology Limited
发明人： Mingdong ZHOU
IPC分类号： A61K38/18
CPC分类号： A61K38/1883 , A61K9/0019 , A61K9/127 , A61K47/60 , A61K48/00
摘要： The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.
摘要翻译：本发明提供了包含用于预防，治疗或延迟各种疾病或障碍的神经调节蛋白的延长释放组合物。本发明还提供了通过延长释放神经调节蛋白来预防，治疗或延迟各种疾病或病症的方法。

90. 发明申请

US20160095902A1 Auris Formulations for Treating Otic Diseases and Conditions 审中-公开
公开(公告)号：US20160095902A1
公开(公告)日：2016-04-07
申请号：US14745160
申请日：2015-06-19
申请人： Otonomy, Inc. , The Regents of the University of California
发明人： Jay Lichter , Andrew M. Trammel , Fabrice Piu , Qiang Ye , Luis A. Dellamary , Carl Lebel , Jeffrey P. Harris , Benedikt Vollrath , Sergio G. Duron , Michael Christopher Scaife
IPC分类号： A61K38/18 , A61K9/06 , A61K9/00
CPC分类号： A61K9/0046 , A61K9/06 , A61K9/127 , A61K9/14 , A61K9/16 , A61K31/05 , A61K31/13 , A61K31/137 , A61K31/325 , A61K31/43 , A61K31/436 , A61K31/519 , A61K31/5513 , A61K31/5517 , A61K38/18 , A61K38/1808 , A61K38/1825 , A61K38/185 , A61K38/1858 , A61K38/1883 , A61K47/14 , A61K47/18 , A61K47/32 , A61K47/38 , A61K2039/505 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式